Carregant...
Current Chemotherapy and Potential New Targets in Uterine Leiomyosarcoma
A variety of chemotherapeutic agents have been used for treating recurrent or advanced stage uterine leiomyosarcoma (ULMS). The response rates of these current agents are disappointing, with partial response rates varying from 0% to 33%, and complete response rates varying from 0% to 8%. Recent stud...
Guardat en:
| Publicat a: | J Clin Med Res |
|---|---|
| Autors principals: | , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Elmer Press
2016
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4737027/ https://ncbi.nlm.nih.gov/pubmed/26858789 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.14740/jocmr2419w |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|